Core Insights - SOPHiA GENETICS has achieved a significant milestone by analyzing over two million genomic profiles on its AI-powered analytics platform, SOPHiA DDM™ [1][2][3] - The rapid growth from one million profiles in 2022 to two million in less than three years highlights the increasing trust in the platform and the transformative role of AI in healthcare [2][4] Company Overview - SOPHiA GENETICS is a cloud-native healthcare technology company focused on expanding access to data-driven medicine, particularly for cancer and rare disorders [10] - The SOPHiA DDM™ platform integrates hundreds of millions of data points across various health dimensions, enhancing its impact on precision medicine [3][4] Platform Capabilities - The SOPHiA DDM™ platform is utilized by 800 healthcare institutions across 72 countries, making it one of the most comprehensive sources of real-world intelligence in precision medicine [2] - The platform analyzes thousands of new oncology and rare disease cases daily, continuously refining its AI capabilities based on real-world data [2][4] Impact on Healthcare - The platform enables faster and more accurate treatment decisions for patients, as evidenced by testimonials from healthcare professionals who have benefited from its use [6][8] - SOPHiA GENETICS's technology allows for effective genetic analyses, including exome sequencing and hereditary cancer testing, without compromising accuracy [6][8] Global Reach and Collaboration - The company collaborates with hospitals and research institutions worldwide, contributing to advanced cancer diagnostics and improving patient care in underserved communities [5][8] - SOPHiA GENETICS will celebrate its milestone at the NVIDIA GTC AI Conference, showcasing its advancements in data-driven medicine [8]